Mr. Franson helped biopharmaceuticals design a step-by-step approach for informing and executing clinical development plans, increasing awareness within the clinician and patient community, and forming the partnerships necessary to accelerate clinical trial completion. client assists.
Chicago, April 17, 2023 /PRNewswire/ — Vaniam Group today announced Paula Franson, MS, APN will lead the company’s clinical strategy and solutions (CSS) delivery. As Senior Vice President, Mr. Franson will help Vanium Group’s global biopharmaceutical clients optimize their clinical trials and maximize the potential of their research and commercial pipelines. She previously served as Vice President of Clinical Strategy for Vaniam Group until 2021.
“We welcome Paula back to the Vaniam Group to lead and grow our clinical strategy capabilities.” Jennifer Buffington Herzog, MPH, President of Vaniam Group. “She has dedicated her entire career to improving oncology care, including over 15 years as a Medical Affairs Executive. and has the industry experience necessary to rapidly bring to market clinical trial results compelling and, above all, that she improves outcomes for all individuals diagnosed with cancer. It’s a personal passion.With Paula’s leadership, Vaniam Group is well-positioned to expand the strategic and consultative value we offer our clients.”
Franson replied: We help clients accelerate clinical trial enrollment worldwide to build clinical strategies and solution offerings. Rapidly identify, diagnose, and resolve critical barriers together.To cancer patients. ”
In addition to his previous role at the Vaniam Group, Mr. Franson has held medical leadership roles at Instil Bio, Tricida, Kite (a Gilead company), Acerta Pharma (a member of the AstraZeneca Group), Celgene, and Pharmacyclics. . , Genentech, Amgen. In addition, she spent her first ten years of her career as an oncology nurse clinician. Franson holds a Bachelor of Science (BSN) in Nursing. Trinity Christian Collegeand her Master of Science in Nursing (MS) Governors State University.
About Banium Group
Vaniam Group is a people-first, purpose-driven, independent company committed to helping biopharmaceutical companies realize the full potential of their compounds across oncology, virology and rare diseases. A network of health care and science communication institutions. Founded in 2007 as a virtual buy him design organization, the Vaniam Group leverages the talent and expertise of its team members around the world. For more information, please visit www.VaniamGroup.com.
Source: Vanium Group LLC
